Quigley now ProPhase Labs
DOYLESTOWN, Pa. Following its annual shareholders meeting held here last week, shareholders voted to change the name of the Quigley Corp. to ProPhase Labs Inc. The name change became effective as of Thursday, May 6. The new corporate Web site will be www.prophaselabs.com.
“The vote was a culmination and affirmation of more than a year of very hard work,” stated ProPhase CEO Ted Karkus. “The shareholder support for our team is very much appreciated. Our new identity sets the stage for a new growth phase for our company by improving our image with our important retailers as well as with investors.”
The roll-out of the corporate identity change to ProPhase Labs will occur over the next six-to-eight weeks, which will include a new corporate log and new packaging for Cold-Eeze and Kids-Eeze.
Native Remedies products to be sold at online retailers
BOCA RATON, Fla. Native Remedies on Wednesday announced that through partnership with Nutritional Products International, their top-selling Internet products now are available at the nation’s foremost online retailers, including Amazon.com, CVS.com and Drugstore.com.
“We are thrilled to have our products available at these top retailers,” stated Native Remedies president George Luntz. “As Native Remedies grows, it is great to have a business partner like NPI helping to expand our market reach. We expect 2010 to be a banner year for us and for NPI.”
Native Remedies features a line of more than 250 herbal and homeopathy products.
Perrigo acquires rights to generic Delsym cough syrup
ALLEGAN, Mich. Perrigo on Wednesday announced that it has acquired the exclusive U.S. store brand rights to sell and distribute dextromethorphan polistirex extended-release suspension cough suppressant — the generic version of Reckitt Benckiser’s Delsym — from Tris Pharma.
Tris believes it has a first-to-file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Tris and Reckitt Benckiser are currently engaged in Paragraph IV/Hatch-Waxman litigation over the Tris ANDA filing. Under the agreement Perrigo and Tris will share profits, and Perrigo will pay Tris certain milestone payments.
Delsym had annual sales of approximately $125 million dollars, Perrigo reported, citing SymphonyIRI data.